SCHEMBL6789612

SCHEMBL6789612

CC1(C(O)c2ccc(-c3ccc(F)c(F)c3)cc2)NC(=O)NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.36
ADAMTS5 Q9UNA0 6/20 0.36
MMP13 P45452 1/20 0.36
ADAM17 P78536 1/20 0.36
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
MMP2 P08253 2/20 0.35
MMP14 P50281 2/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
MMP8 P22894 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
IDH1 O75874 1/20 0.32
ANPEP P15144 1/20 0.32
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
CTSS P25774 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795148 0.86 AKR1B1 (0.35) ADAMTS5
SCHEMBL6835790 0.85 FFAR1 (0.41) PGRADAMTS5MMP13MMP2
SCHEMBL6790620 0.83 MMP2 (0.43) PGRADAMTS5MMP13ADAM17MMP2
SCHEMBL6791153 0.82 MMP2 (0.41) MMP2MMP8PTGS2
SCHEMBL6791227 0.82 MMP2 (0.41) MMP2MMP8PTGS2
SCHEMBL6789361 0.82 MMP2 (0.41) MMP2MMP8PTGS2
SCHEMBL8339982 0.81 PGR (0.41) PGRADAMTS5MMP13ADAM17AKR1C3
SCHEMBL6792396 0.81 PTGER3 (0.46) AKR1C3AKR1C2
SCHEMBL6798425 0.80 CYP17A1 (0.37) MMP13ADAM17DPP4AR
SCHEMBL6827189 0.80 ESR1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 PGR 746/4885ADAMTS5 28/4885MMP13 6/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PGR 860/4885ADAMTS5 48/4885MMP13 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.